PriceTargets.com logo

Dyne Therapeutics - DYN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $51.40
  • Forecasted Upside: 71.39%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$29.99 As of 11/20/2024 01:00 AM ET
▲ +0.31 (1.04%)

This chart shows the closing price for DYN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dyne Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DYN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DYN

Analyst Price Target is $51.40
▲ +71.39% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $51.40, with a high forecast of $66.00 and a low forecast of $35.00. The average price target represents a 71.39% upside from the last price of $29.99.

This chart shows the closing price for DYN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Dyne Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024Chardan CapitalReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
10/24/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$43.00 ➝ $35.00
9/23/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$53.00 ➝ $53.00
9/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
9/3/2024OppenheimerReiterated RatingOutperform ➝ Outperform$55.00 ➝ $55.00
8/16/2024Stifel NicolausBoost TargetBuy ➝ Buy$41.00 ➝ $66.00
8/15/2024GuggenheimBoost TargetBuy ➝ Buy$45.00 ➝ $50.00
8/14/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$48.00 ➝ $52.00
8/13/2024HC WainwrightBoost TargetBuy ➝ Buy$48.00 ➝ $55.00
8/13/2024Piper SandlerBoost TargetOverweight ➝ Overweight$43.00 ➝ $53.00
7/9/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$39.00 ➝ $43.00
5/21/2024Chardan CapitalBoost TargetBuy ➝ Buy$31.00 ➝ $42.00
5/20/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$36.00 ➝ $42.00
5/20/2024HC WainwrightBoost TargetBuy ➝ Buy$36.00 ➝ $48.00
5/6/2024OppenheimerReiterated RatingOutperform ➝ Outperform$47.00 ➝ $47.00
5/6/2024Chardan CapitalReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00
4/30/2024Morgan StanleyInitiated CoverageOverweight$40.00
3/26/2024OppenheimerReiterated RatingOutperform ➝ Outperform$47.00
3/8/2024Chardan CapitalBoost TargetBuy$20.00 ➝ $31.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00
3/6/2024Stifel NicolausBoost TargetBuy ➝ Buy$35.00 ➝ $41.00
3/6/2024Piper SandlerBoost TargetOverweight ➝ Overweight$27.00 ➝ $29.00
3/5/2024OppenheimerReiterated RatingOutperform ➝ Outperform$44.00 ➝ $47.00
2/20/2024HC WainwrightInitiated CoverageBuy$36.00
1/4/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$27.00 ➝ $56.00
8/9/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$20.00 ➝ $22.00
8/4/2023Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
3/3/2023Chardan CapitalBoost TargetBuy$17.00 ➝ $20.00
2/27/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$16.00 ➝ $27.00
2/14/2023OppenheimerInitiated CoverageOutperform$34.00
1/26/2023GuggenheimInitiated CoverageBuy$33.00
11/29/2022JPMorgan Chase & Co.Lower Target$24.00 ➝ $18.00
11/4/2022Raymond JamesBoost TargetOutperform$15.00 ➝ $16.00
9/6/2022Piper SandlerBoost Target$17.00 ➝ $23.00
7/20/2022Chardan CapitalInitiated CoverageBuy$17.00
7/12/2022Piper SandlerBoost Target$12.00 ➝ $17.00
7/11/2022Raymond JamesInitiated CoverageOutperform$15.00
5/23/2022Piper SandlerLower TargetOverweight$16.00 ➝ $12.00
3/11/2022Stifel NicolausReiterated RatingBuy$29.00
2/9/2021JonestradingInitiated CoverageBuy
10/12/2020JPMorgan Chase & Co.Initiated CoverageOverweight$27.00
10/12/2020Stifel NicolausInitiated CoverageBuy$29.00
10/12/2020Piper SandlerInitiated CoverageOverweight$34.00
10/12/2020Jefferies Financial GroupInitiated CoverageBuy$47.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 16 very positive mentions
  • 27 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 12 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 17 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 18 very positive mentions
  • 25 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 20 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 9 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 9 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Dyne Therapeutics logo
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $29.99
Low: $28.68
High: $30.28

50 Day Range

MA: $32.31
Low: $28.13
High: $36.59

52 Week Range

Now: $29.99
Low: $10.03
High: $47.45

Volume

1,087,662 shs

Average Volume

1,086,944 shs

Market Capitalization

$3.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Dyne Therapeutics?

The following Wall Street research analysts have issued stock ratings on Dyne Therapeutics in the last twelve months: Chardan Capital, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Stifel Nicolaus, and StockNews.com.
View the latest analyst ratings for DYN.

What is the current price target for Dyne Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Dyne Therapeutics in the last year. Their average twelve-month price target is $51.40, suggesting a possible upside of 71.4%. Stifel Nicolaus has the highest price target set, predicting DYN will reach $66.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $35.00 for Dyne Therapeutics in the next year.
View the latest price targets for DYN.

What is the current consensus analyst rating for Dyne Therapeutics?

Dyne Therapeutics currently has 1 hold rating, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DYN will outperform the market and that investors should add to their positions of Dyne Therapeutics.
View the latest ratings for DYN.

What other companies compete with Dyne Therapeutics?

Other companies that are similar to Dyne Therapeutics include Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals, Protagonist Therapeutics, Amphastar Pharmaceuticals and Five Prime Therapeutics. Learn More about companies similar to Dyne Therapeutics.

How do I contact Dyne Therapeutics' investor relations team?

Dyne Therapeutics' physical mailing address is 1560 Trapelo Road, Waltham, MA 02451, United States. The company's listed phone number is 781-786-8230 and its investor relations email address is [email protected]. The official website for Dyne Therapeutics is www.dyne-tx.com. Learn More about contacing Dyne Therapeutics investor relations.